India, which supplies many drugs and active ingredients to the US market, has come under increasing scrutiny after tainted cough syrup made in that country killed at least 89 children in Gambia and Uzbekistan in 2022. And recently, US regulators have stepped up their foreign inspections after a pandemic pause, unleashing a slew of warning letters on serious manufacturing missteps.
